Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study

25 de março de 2021 atualizado por: USDA, Western Human Nutrition Research Center

Assessing the Impact of Diet on Inflammation in Healthy and Obese Adults in a Cross-Sectional Phenotyping Study

Although the diet of the US population meets or exceeds recommended intake levels of most essential nutrients, the quality of the diet consumed by many Americans is sub-optimal due to excessive intake of added sugars, solid fats, refined grains, and sodium. The foundations and outcomes of healthy vs. unhealthy eating habits and activity levels are complex and involve interactions between the environment and innate physiologic/genetic background. For instance, emerging research implicates chronic and acute stress responses and perturbations in the Hypothalamic-Pituitary-Adrenal axis in triggering obesity-promoting metabolic changes and poor food choices. In addition, the development of many chronic diseases, including cardiovascular disease, diabetes, cancer, asthma and autoimmune disease, results from an overactive immune response to host tissue or environmental antigens (e.g. inhaled allergens). A greater understanding is needed of the distribution of key environment-physiology interactions that drive overconsumption, create positive energy balance, and put health at risk.

Researchers from the United States Department of Agriculture (USDA) Western Human Nutrition Research Center are conducting a cross-sectional "metabolic phenotyping" study of healthy people in the general population. Observational measurements include the interactions of habitual diet with the metabolic response to food intake, production of key hormones, the conversion of food into energy: the metabolism of fats, proteins, and carbohydrates, characteristics of the immune system, stress response, gut microbiota (bacteria in the intestinal tract), and cardiovascular health. Most outcomes will be measured in response to a mixed macronutrient/high fat challenge meal.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

Many inflammatory responses can be modulated by specific dietary components. For example, in cardiovascular disease, macrophages and T-cells react with oxidized LDL (an endogenous modified antigen) to produce arterial plaque and subsequent blockage of coronary arteries. High intake of saturated fats (or simple sugars that drive synthesis of saturated fatty acids) may promote this inflammation by affecting macrophages and T-cells. Conversely, increased intake of omega-3 fatty acids may decrease inflammation by suppression of macrophage and T-cell pro-inflammatory activity. Long-term sub-clinical inflammation caused by intestinal bacteria has been linked to the development of Irritable Bowel Disease and related disorders. Low intake of fruits, vegetables, or whole grains or high intake of saturated fats may promote sub-clinical gut inflammation by promoting dysbiosis of the gut microbiota. Allergic asthma develops in predisposed individuals as a result of an overactive allergic-type immune response to inhaled environmental allergens. Dietary factors such as vitamin D and omega-3 fatty acids may diminish pro-inflammatory responses to environmental allergens by promoting the development of T-regulatory cells and other anti-inflammatory factors.

Individual variability in chronic disease risk is well recognized. For example, why does excess adiposity lead to disease in some individuals and not others? The nature of the fat tissue rather than the abundance, may impact cross-talk with other metabolically-relevant tissues and affect disease risk. It is important to characterize healthy vs. unhealthy phenotypes across various tissues and to understand how micro- and macro-nutrients interact with molecular and metabolic pathways to support a healthy body weight. This study brings together scientists with expertise in nutritional sciences, immunology, analytical chemistry, physiology, neuroendocrinology, and behavior to understand how diet impacts metabolism and disease risk through the interplay and coordination of signals and metabolites arising from multiple organ systems.

The overall objective is to characterize the phenotypic profile of participants according to their immunologic, physiologic, neuroendocrine, and metabolic responses to a dietary challenge and a physical fitness challenge by addressing the specific aims listed below. The cross-sectional study is organized into two study visits (Visit 1 and Visit 2) separated by approximately two weeks of at-home specimen and data collection.

Specific Aim 1: To determine if diet quality is independently associated with systemic immune activation, inflammation, or oxidative stress differentiated by:

  1. pro-inflammatory T-helper cells (Th1, Th2, and Th17 cells) and related cytokines
  2. anti-inflammatory T-regulatory cells and related cytokines
  3. dysbiosis of the gut microbiota and markers of gut inflammation (e.g. neopterin and myeloperoxidase)

    a. and to evaluate the association between dysbiosis of the gut microbiota, gut inflammation, and systemic immune activation

  4. plasma metabolomic response to a mixed macronutrient challenge meal (includes diet quality and physical activity as independent variables)
  5. endothelial (dys)function and vascular reactivity

Specific Aim 2: To determine if a high fat/sugar challenge meal induces differential effects over time (0-6h postprandial) according to habitual diet characteristics, physical activity levels, stress levels, age, sex, or BMI on:

  1. postprandial monocyte activation
  2. plasma lipid metabolomic responses including non-esterified fatty acids, phospholipids, triacylglycerols, red blood cell fatty acids, endocannabinoids, bile acids, eicosanoids and related oxylipins, ceramides, sphingoid bases, and acylcarnitines
  3. plasma amino acid metabolomics
  4. glucose metabolism and metabolic flexibility (i.e. the ability to switch from glucose to lipid oxidation as energy sources)
  5. changes in endocrinology and self-report of hunger and satiety
  6. postprandial free cortisol

Specific Aim 3: To determine the mechanisms of:

  1. postprandial monocyte activation
  2. suppression of challenge-meal induced monocyte activation by docosahexaenoic acid (DHA) (in an ex vivo experiment using a subset of samples)

Specific Aim 4: To evaluate the associations between eating behavior, physical activity, and/or anthropometry and the outcomes:

  1. endocrinology of hunger and satiety
  2. plasma metabolomic responses
  3. vulnerability and resistance to stress
  4. endothelial (dys)function and vascular reactivity
  5. prediction of insulin sensitivity

Specific Aim 5: To determine how genetic variants affect nutrient metabolism, cardiovascular physiology, and immune function and improve understanding of how dietary factors affect these metabolic, cardiovascular and immune phenotypes.

Tipo de estudo

Observacional

Inscrição (Real)

393

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Davis, California, Estados Unidos, 95616
        • USDA, Western Human Nutrition Research Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Healthy people in the general population

Descrição

Inclusion Criteria:

  • 18-65 y
  • Male or female
  • Body Mass Index 18.5-45.0 kg/m2 (Normal to obese)

Exclusion Criteria:

  • Pregnant or lactating women
  • Known allergy to egg-white protein
  • Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg measured on three separate occasions
  • Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:

    • Diabetes mellitus
    • Cardiovascular disease
    • Cancer
    • Gastrointestinal disorders
    • Kidney disease
    • Liver disease
    • Bleeding disorders
    • Asthma
    • Autoimmune disorders
    • Hypertension
    • Osteoporosis
  • Recent minor surgery (within 4 wk) or major surgery (within 16 wk)
  • Recent antibiotic therapy (within 4 wk)
  • Recent hospitalization (within 4 wk)
  • Use of prescription medications at the time of the study that directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control, steroids, statins, anti-inflammatory agents, and over-the-counter weight loss aids)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Sampling strata
Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Baseline level and change in systemic immune activation following challenge meal
Prazo: 0, 0.5, 3, and 6 hours postprandial
Number and activation level of pro-inflammatory T-helper (Th) cells (Th1, Th2 and Th17), T-regulatory (Treg) cells, and B cells will be measured in fasting blood. Monocytes and neutrophils will be measured in fasting and postprandial blood.
0, 0.5, 3, and 6 hours postprandial
Baseline level and change in plasma metabolome
Prazo: 0, 0.5, 3, and 6 hours postprandial
Plasma fatty acid profiles of non-esterified fatty acids, phospholipids, triacylglycerols, red blood cell fatty acids, endocannabinoids, bile acids, eicosanoids and related oxylipins, ceramides, sphingoid bases, acylcarnitines, amino acids and other metabolites measured in response to a challenge meal.
0, 0.5, 3, and 6 hours postprandial

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Baseline level and change in glucose metabolism
Prazo: 0, 0.5, 3, and 6 hours postprandial
Glucose and insulin measured in response to a challenge meal.
0, 0.5, 3, and 6 hours postprandial
Baseline level and change in appetitive hormones
Prazo: 0, 0.5, 3, and 6 hours postprandial
Cholecystokinin, incretins, Peptide YY 3-36, ghrelin measured in response to a challenge meal.
0, 0.5, 3, and 6 hours postprandial
Baseline level and change in mitogen activated protein (MAP) kinase activity
Prazo: 0, 0.5, 3 and 6 hours postprandial
Mononuclear cells or B cells will be measured for MAP kinase activities in fasting and postprandial blood.
0, 0.5, 3 and 6 hours postprandial
Baseline level and change in dietary-responsive, circulating microRNA
Prazo: 0, 0.5, 3, and 6 hours postprandial
Plasma microRNA measured in response to a challenge meal
0, 0.5, 3, and 6 hours postprandial
Baseline level and change in RNA transcriptome
Prazo: 0, 3, and 6 hours postprandial
Transcriptome RNA sequenced in whole blood
0, 3, and 6 hours postprandial
Genome Wide Association Study (GWAS)
Prazo: 0 hours (fasting)
DNA sequence from whole blood will be analyzed
0 hours (fasting)
General health
Prazo: 0 hours (Fasting)
Clinical chemistry panel and complete blood count
0 hours (Fasting)
Anthropometrics
Prazo: single time point
Height (cm), weight (kg), waist and hip circumference (cm)
single time point
Vital signs
Prazo: single time point
Blood pressure (mmHg), pulse rate (beats per minute) and temperature (degrees F).
single time point
Body composition
Prazo: single time point
Body composition (percent body fat) and bone mineral density by Dual energy X-ray Absorptiometry scan.
single time point
Resting and change in metabolism
Prazo: 0, 0.5, 3, and 6 hours postprandial
Resting and postprandial metabolic rates, including respiratory exchange ratios.
0, 0.5, 3, and 6 hours postprandial
Gut microbiota
Prazo: single time point
Gut microbiota composition and gene content will be assessed in stool using polymerase chain reaction (PCR) and sequencing
single time point
Gut microbiota fermentation capacity
Prazo: single time point
The fermentation capacity of microbiota will be measured from a single stool sample
single time point
Gut microbiota pathogen resistance capacity
Prazo: single time point
The pathogen resistance capability of microbiota will be measured from a single stool sample
single time point
Gut inflammation
Prazo: single time point
Gut inflammation will be assessed by measuring molecules in stool and/or the response of intestinal epithelial cell cultures to fecal waters from a single stool sample.
single time point
Stool metabolites
Prazo: single time point
Volatile and short chain fatty acids and bile acids will be measured in a single stool sample.
single time point
Stool RNA markers
Prazo: single time point
RNA markers will provide a measure of genes expressed by cells of the colon naturally present in a single stool sample
single time point
Baseline and change in hunger and appetite
Prazo: 0, 1, 2, 3, 4, 5, and 6 hours postprandial
Perceived hunger and fullness will be measured using a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 5 or "extremely."
0, 1, 2, 3, 4, 5, and 6 hours postprandial
Baseline and change in gut fermentation profile
Prazo: 0, 1, 2, 3, 4, 5, and 6 hours postprandial
Breath hydrogen and methane measured in response to a challenge meal.
0, 1, 2, 3, 4, 5, and 6 hours postprandial
Recent dietary intake
Prazo: Three 24-hour dietary recalls collected at home
Random selection of 2 week days and 1 weekend day for 24-hour recall using an automated multi-pass method
Three 24-hour dietary recalls collected at home
Dietary intake
Prazo: single time point
Food frequency questionnaire (FFQ)
single time point
Behavior assessment
Prazo: single time point
Chronic stress questionnaire, food choice questionnaires, and a food preference activity.
single time point
Taste thresholds
Prazo: single time point
Sampling tastes of sweet, salty, and bitter solutions in comparison to water to determine threshold of taste detection.
single time point
Skin reflectance
Prazo: single time point
Spectrophotometric measure of skin pigmentation for assessment of vitamin D status.
single time point
Peripheral arterial tone
Prazo: single time point
Use of the EndoPAT system to measure blood vessel tone.
single time point
Pulmonary function
Prazo: single time point
Forced expiratory lung volume test
single time point
Pulmonary inflammation
Prazo: single time point
Pulmonary inflammation measured as exhaled nitric oxide (NO)
single time point
Executive function
Prazo: single time point
Executive function will be assessed using Cambridge Neuropsychological Test Automated Battery (CANTAB) and Iowa Gambling Task
single time point
Cognitive function
Prazo: single time point
Measured by Wechsler Abbreviated Standard Intelligence test.
single time point
Aerobic fitness assessment
Prazo: single time point
Pulse rate (bpm) and recovery after a 3 min YMCA Step Test
single time point
Submaximal oxygen consumption
Prazo: single time point
The submaximal volume of oxygen consumed during a 4 minute treadmill walking protocol (VO2max) (ml/kg*min)
single time point
Physical activity
Prazo: daily, for 7 days
Use of an accelerometer worn on the hip for 7 days
daily, for 7 days
Usual physical activity
Prazo: single time point
Activity recall using a questionnaire
single time point
Heart rate variability and autonomic nerve conductivity
Prazo: single time point
Monitoring of autonomic balance, cardiac performance, and respiratory measurements and activity using MindWare Mobile Impedance Cardiograph.
single time point
Allostatic Load
Prazo: single time point
An aggregate score derived from measures of urinary cortisol, norepinephrine, epinephrine, blood cholesterol, high sensitivity c-reactive protein, and hemoglobin A1C.
single time point
Baseline and change in salivary cortisol in response to test meal
Prazo: 0, immediately post-prandial, 30, 60, and 90 minutes post-prandial
Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)
0, immediately post-prandial, 30, 60, and 90 minutes post-prandial
Baseline and change in salivary cortisol in response to exercise
Prazo: 0, immediately post-exercise, 30, 60, and 90 minutes post-exercise
Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)
0, immediately post-exercise, 30, 60, and 90 minutes post-exercise
Baseline and change in salivary cortisol in response to emotional recall task
Prazo: 0, immediately post-task, 30, 60, and 90 minutes post-task
Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)
0, immediately post-task, 30, 60, and 90 minutes post-task
Baseline and change in breath aldehydes
Prazo: 0, 1, 4 and 6 hours postprandial
The concentration of aldehydes present in human breath before and after a high-fat meal will be measured by mass spectrometry
0, 1, 4 and 6 hours postprandial

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Charles B Stephensen, Ph.D., USDA, Western Human Nutrition Research Center
  • Investigador principal: Brian J Bennett, Ph.D., USDA, Western Human Nutrition Research Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de maio de 2015

Conclusão Primária (Real)

24 de julho de 2019

Conclusão do estudo (Real)

24 de julho de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

12 de fevereiro de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de fevereiro de 2015

Primeira postagem (Estimativa)

20 de fevereiro de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de março de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de março de 2021

Última verificação

1 de março de 2021

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 691654
  • 2032-53000-001-00 (Número de outro subsídio/financiamento: United States Department of Agriculture)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever